Trial Profile
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 05 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 02 Mar 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 22 Feb 2022 Interventional Study Model changed to Single Group Assignment, number of treatment arms changed to 1